The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Role of Toll‐like receptors in the pathogenesis of COVID‐19
Open accessAbstract
Coronavirus disease 2019 (COVID‐19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), has led to a pandemic since March 2020. The exact pathogenesis of SARS‐CoV‐2 and the role of each component of the innate and adaptive immune system is still unknown. However, available data from other coronavirus families, such as SARS‐CoV and the Middle East respiratory syndrome and also new findings could be useful for a better understanding of SARS‐CoV‐2. Toll‐like receptors (TLR) play an important role in recognition of viral particles and activation of the innate immune system. Activation of TLR pathways leads to secretion of pro‐inflammatory cytokines, such as interleukin‐1 (IL‐1), IL‐6, and tumor necrosis factor‐α, as well as type 1 interferon. Different TLRs, like TLR2, TLR3, TLR4, TLR6, TLR7, TLR8, and TLR9 are potentially important in COVID‐19 infection. It is also worth mentioning that we should bear in mind both the beneficial and harmful effects of TLR in confronting COVID‐19 infection. TLRs could be a potential target in controlling the infection in the early stages of disease and production of vaccine against SARS‐CoV‐2.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Conti, P. (2020) · Journal of Biological Regulators and Homeostatic Agents · doi:10.23812/conti-e · Cited by 1,227
SARS-CoV-2–triggered neutrophil extracellular traps mediate COVID-19 pathology
Veras, F. P., Pontelli, M. C., Silva, C. M., Toller-Kawahisa, J. E., de Lima, M., Nascimento, D. C., Schneider, A. H., Caetité, D., Tavares, L. A., Paiva, I. M., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20201129 · Cited by 933
Presence of Genetic Variants Among Young Men With Severe COVID-19
van der Made, C. I., Simons, A., Schuurs-Hoeijmakers, J., van den Heuvel, G., Mantere, T., Kersten, S., van Deuren, R. C., Steehouwer, M., van Reijmersdal, S. V., Jaeger, M., et al. (2020) · JAMA · doi:10.1001/jama.2020.13719 · Cited by 789
Toll-Like Receptors in Antiviral Innate Immunity
Lester, S. N., & Li, K. (2014) · Journal of Molecular Biology · doi:10.1016/j.jmb.2013.11.024 · Cited by 735
Choudhury, A., & Mukherjee, S. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25987 · Cited by 488
Totura, A. L., Whitmore, A., Agnihothram, S., Schäfer, A., Katze, M. G., Heise, M. T., & Baric, R. S. (2015) · mBio · doi:10.1128/mbio.00638-15 · Cited by 455
Coronavirus COV-19/SARS-CoV-2 affects women less than men: clinical response to viral infection.
Conti, P. (2020) · JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS · doi:10.23812/editorial-conti-3 · Cited by 442
Immune-mediated approaches against COVID-19
Florindo, H. F., Kleiner, R., Vaskovich-Koubi, D., Acúrcio, R. C., Carreira, B., Yeini, E., Tiram, G., Liubomirski, Y., & Satchi-Fainaro, R. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-0732-3 · Cited by 338
The immune system and COVID-19: Friend or foe?
Yazdanpanah, F., Hamblin, M. R., & Rezaei, N. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117900 · Cited by 270
Self-citationSohn, K. M., Lee, S.-G., Kim, H. J., Cheon, S., Jeong, H., Lee, J., Kim, I. S., Silwal, P., Kim, Y. J., Paik, S., et al. (2020) · Journal of Korean Medical Science · doi:10.3346/jkms.2020.35.e343 · Cited by 199
Cicco, S., Cicco, G., Racanelli, V., & Vacca, A. (2020) · Mediators of Inflammation · doi:10.1155/2020/7527953 · Cited by 189
Moreno-Eutimio, M. A., López-Macías, C., & Pastelin-Palacios, R. (2020) · Microbes and Infection · doi:10.1016/j.micinf.2020.04.009 · Cited by 178
COVID 19: a clue from innate immunity
Birra, D., Benucci, M., Landolfi, L., Merchionda, A., Loi, G., Amato, P., Licata, G., Quartuccio, L., Triggiani, M., & Moscato, P. (2020) · Immunologic Research · doi:10.1007/s12026-020-09137-5 · Cited by 166
Genetic gateways to COVID‐19 infection: Implications for risk, severity, and outcomes
Debnath, M., Banerjee, M., & Berk, M. (2020) · The FASEB Journal · doi:10.1096/fj.202001115r · Cited by 158
Recent insights into the role of Toll-like receptors in viral infection
Carty, M., & Bowie, A. (2010) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.2010.04196.x · Cited by 151
Symptomatic Protective Action of Glycyrrhizin (Licorice) in COVID-19 Infection?
Murck, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01239 · Cited by 145
Targeting of Toll-like receptors: a decade of progress in combating infectious diseases
Hedayat, M., Netea, M. G., & Rezaei, N. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70099-8 · Cited by 132
Self-citationKhadke, S., Ahmed, N., Ahmed, N., Ratts, R., Raju, S., Gallogly, M. M., Lima, M. J. G. D., & Sohail, M. R. (2020) · Virology Journal · doi:10.1186/s12985-020-01415-w · Cited by 131
Durai, P., Batool, M., Shah, M., & Choi, S. (2015) · Experimental & Molecular Medicine · doi:10.1038/emm.2015.76 · Cited by 129
Toll-Like Receptors and COVID-19: A Two-Faced Story with an Exciting Ending
Onofrio, L., Caraglia, M., Facchini, G., Margherita, V., Placido, S. D., & Buonerba, C. (2020) · Future Science OA · doi:10.2144/fsoa-2020-0091 · Cited by 121
Targeting human TLRs to combat COVID‐19: A solution?
Patra, R., Das, N. C., & Mukherjee, S. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26387 · Cited by 120
SARS‐CoV‐2: A comprehensive review from pathogenicity of the virus to clinical consequences
Lotfi, M., & Rezaei, N. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26123 · Cited by 118
Self-citationPathologic features of COVID-19: A concise review
Tabary, M., Khanmohammadi, S., Araghi, F., Dadkhahfar, S., & Tavangar, S. M. (2020) · Pathology - Research and Practice · doi:10.1016/j.prp.2020.153097 · Cited by 109
Self-citationInterleukin-6 and severe COVID-19: a systematic review and meta-analysis
Mojtabavi, H., Saghazadeh, A., & Rezaei, N. (2020) · European Cytokine Network · doi:10.1684/ecn.2020.0448 · Cited by 104
Self-citationThe Inflammasome in Times of COVID-19
Vaccari, J. C. D. R., Dietrich, W. D., Keane, R. W., & Vaccari, J. P. D. R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.583373 · Cited by 104
Proud, P. C., Tsitoura, D. C., Watson, R. J., Chua, B. Y. L., Aram, M. J., Bewley, K. R., Cavell, B. E., Cobb, R., Dowall, S., Fotheringham, S. A., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.103153 · Cited by 98
mTOR inhibition and p53 activation, microRNAs: The possible therapy against pandemic COVID-19
Ramaiah, M. J. (2020) · Gene Reports · doi:10.1016/j.genrep.2020.100765 · Cited by 91
Mazaleuskaya, L., Veltrop, R., Ikpeze, N., Martin-Garcia, J., & Navas-Martin, S. (2012) · Viruses · doi:10.3390/v4050901 · Cited by 89
Imiquimod - A toll like receptor 7 agonist - Is an ideal option for management of COVID 19
Angelopoulou, A., Alexandris, N., Konstantinou, E. K., Mesiakaris, K., Zanidis, C., Farsalinos, K. E., & Poulas, K. A. (2020) · Environmental Research · doi:10.1016/j.envres.2020.109858 · Cited by 87
de Groot, N. G., & Bontrop, R. E. (2020) · Immunogenetics · doi:10.1007/s00251-020-01165-7 · Cited by 50
Mesenchymal Stem Cells in COVID-19: A Journey from Bench to Bedside
Sahu, K. K., Siddiqui, A. D., & Černý, J. (2020) · Laboratory Medicine · doi:10.1093/labmed/lmaa049 · Cited by 32
Implications of Toll-like receptors in Ebola infection
Saghazadeh, A., & Rezaei, N. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1299128 · Cited by 27
Self-citationAlnefaie, A., & Albogami, S. M. (2020) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2020.08.024 · Cited by 26
Cited by
Lamers, M. M., & Haagmans, B. L. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00713-0 · Cited by 983
SARS-CoV-2, COVID-19 and the aging immune system
Bartleson, J. M., Radenkovic, D., Covarrubias, A. J., Furman, D., Winer, D. A., & Verdin, E. (2021) · Nature Aging · doi:10.1038/s43587-021-00114-7 · Cited by 359
Monocytes and Macrophages in COVID-19
Knoll, R., Schultze, J. L., & Schulte-Schrepping, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.720109 · Cited by 266
Toll-like receptor 4: A potential therapeutic target for multiple human diseases
Wei, J., Zhang, Y., Li, H., Wang, F., & Yao, S. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115338 · Cited by 121
Tripathi, U., Nchioua, R., Prata, L. G. P. L., Zhu, Y., Gerdes, E. O. W., Giorgadze, N., Pirtskhalava, T., Parker, E., Xue, A., Espindola-Netto, J. M., et al. (2021) · Aging · doi:10.18632/aging.203560 · Cited by 88
Metadata
- Authors
- Khanmohammadi, S., & Rezaei, N.
- Venue
- Journal of Medical Virology
- Publisher
- Wiley
- Published
- 2021-02-09
- Volume
- 93
- Issue
- 5
- Pages
- 2735-2739
- ISSN
- 0146-6615 (ISSN-L)
- 1096-9071
- OpenAlex
- W3123199686
- Cited by
- 370
- References
- 33
- FWCI
- 23.35
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.